Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 is reflected on the page.
    Difference
    0.0%
    Check dated 2026-03-19T04:55:39.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T00:55:21.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed Revision: v3.4.1 along with related funding status notices; these are system-level updates that do not alter study details.
    Difference
    0.4%
    Check dated 2026-02-11T11:37:39.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding status and updated the platform version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:36:53.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    These updates include additions of a glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, and deletions of the prior variants Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:31:54.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4. This is a minor technical update and does not affect any study details or data.
    Difference
    0.0%
    Check dated 2026-01-14T02:17:38.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.